For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring a…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing. That…
Blog
The unseen costs of banning PBM-owned pharmacies in Tennessee
Tennessee lawmakers recently passed the FAIR Rx Act, which would bar companies from owning pharmacies while also operating a pharmacy benefit manager (PBM) and…
Search Posts
Comment
CEI Comments on Labor Union Dues – Skimming of Medicaid Benefits
On behalf of the Competitive Enterprise Institute (CEI), I respectfully submit these comments in response to the Centers for Medicare & Medicaid Services (CMS) Notice…
Blog
Protect Home Healthcare Providers: End Dues Skimming
Our friends at the State Policy Network have produced a compelling new video about the plight of men and women who have been forced…
SCPR
AUDIO: Marc Scribner Discusses Driverless Cars and State Safety Regulations on AirTalk
CEI Senior Fellow Marc Scribner joined AirTalk on Southern California Public Radio to discuss driverless car technology and state safety regulations.
The Washington Examiner
Trump Keeps His Promise, Dying Patients Get a Second Chance At Life
The Washington Examiner cited the Competitive Enterprise Institute on the direct toll to human life that regulations impose as a result of ever-increasing FDA clinical…
The Hill
‘Right to Try’ Is a Win for Patient Rights and President Trump
The Hill cited the Competitive Enterprise Institute on the overwhelming cost of compliance which taxes the American economy and in this case limits pharmaceutical ingenuity…
Blog
Congress Could Give Desperate Patients ‘Right to Try’ Experimental Medications
The House of Representatives will soon vote on a companion bill to S. 204, the Right to Try Act. This bill would prevent the…